Enochian Biosciences, Inc. (ENOB)


+0.01 (+1.79%)
Symbol ENOB
Price $0.7125
Beta 0.940
Volume Avg. 0.25M
Market Cap 45.385M
Shares () -
52 Week Range 0.393-2.99
1y Target Est -
DCF Unlevered ENOB DCF ->
DCF Levered ENOB LDCF ->
ROE -561423.10% Strong Sell
ROA -491982.64% Strong Sell
Operating Margin -
Debt / Equity 10.64% Neutral
P/E -0.34 Neutral
P/B 0.60 Buy


Consensus EPS

Upgrades & Downgrades

Latest ENOB news

Dr. Mark R. Dybul M.D.
NASDAQ Capital Market

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.